That's still $150 million for something that might never see the shelves. And the $100 million will be spent on the Phase III trial.At $3.50 it is still richly valued. This correction was well overdue.
Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game